Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

Analysis of Solvency Ratios 
Quarterly Data

Microsoft Excel

Solvency Ratios (Summary)

AbbVie Inc., solvency ratios (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Debt Ratios
Debt to equity 49.22 20.19 11.78 10.42 9.24 5.73 5.02 4.74 4.68 3.67 4.35 4.98 4.51 4.98 5.96 6.53 6.24 6.58 5.70 5.94
Debt to capital 1.00 0.98 0.95 0.92 0.91 0.90 0.85 0.83 0.83 0.82 0.79 0.81 0.83 0.82 0.83 0.86 0.87 0.86 0.87 0.85 0.86 1.12
Debt to assets 0.51 0.51 0.50 0.50 0.50 0.50 0.44 0.45 0.45 0.46 0.46 0.49 0.51 0.51 0.52 0.54 0.56 0.57 0.57 0.58 0.58 0.74
Financial leverage 95.89 40.65 23.78 20.94 18.59 13.00 11.26 10.52 10.14 8.04 8.84 9.77 8.80 9.51 10.99 11.77 10.98 11.51 9.80 10.17

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).


The analysis of the financial leverage and debt-related ratios over the observed periods reveals several key trends and shifts in the company's capital structure.

Debt to Equity Ratio
This ratio shows marked volatility throughout the timeline. Initially, it ranged moderately around values between approximately 5.7 and 6.6 during 2020 and 2021, indicating a consistent reliance on debt relative to shareholders' equity. Beginning in 2022, the ratio generally trended downward, hitting a low near 3.67 by December 2022, suggesting a temporary reduction in debt relative to equity. However, from 2023 onward, the ratio surged sharply, culminating in a peak of 49.22 by June 2025, which reflects a considerable increase in leverage and potentially higher financial risk.
Debt to Capital Ratio
The debt to capital ratio remained relatively stable early on, fluctuating slightly around the 0.85 to 0.87 range during 2020 and 2021. In 2022 and 2023, the ratio saw a slight decrease towards 0.79, implying a modest reduction in the proportion of debt in the overall capital base. From 2024 onwards, the ratio increased steadily, reaching nearly 1.0 by June 2025, reflecting a capital structure almost entirely composed of debt.
Debt to Assets Ratio
This ratio exhibited a declining trend from 0.74 in March 2020 down to about 0.45 in late 2023, indicating a gradual decline in debt relative to total assets during this period. Nonetheless, starting in 2024, the ratio stabilized around 0.50 to 0.51, suggesting that about half of the company’s assets are financed with debt going into 2025.
Financial Leverage Ratio
Financial leverage mirrored the fluctuations seen in the debt to equity ratio. It ranged from about 9.8 to 11.5 in the early period (2020-2021), dipped to a low near 8.0 by late 2022, then escalated sharply from 10.14 in early 2023 to an extreme level of 95.89 by mid-2025. This spike indicates a substantial increase in the use of debt financing relative to equity, pointing to magnified financial risk and potentially increased burden on earnings through interest costs.

Overall, the data suggest that the company experienced a period of moderately high leverage with some reduction between 2021 and 2023, followed by an aggressive increase in debt levels relative to equity, capital, and assets, particularly in recent quarters through mid-2025. The dramatic rise in leverage ratios highlights a shift towards a more debt-intensive capital structure, which could have significant implications for financial risk and future funding flexibility.


Debt Ratios


Debt to Equity

AbbVie Inc., debt to equity calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in millions)
Short-term borrowings 5,556 1,593 3 2 1 1 10 17 12 14 16 17 9 34 54 64 6
Current portion of long-term debt and finance lease obligations 1,966 3,769 6,804 12,570 12,586 10,193 7,191 5,113 5,203 2,800 4,135 9,197 11,913 9,940 12,481 6,656 7,884 11,338 8,468 4,723 5,307 3,756
Long-term debt and finance lease obligations, excluding current portion 62,959 64,527 60,340 58,509 58,048 63,805 52,194 55,631 55,812 59,292 59,135 60,399 61,002 63,522 64,189 74,049 74,237 74,183 77,554 82,282 82,061 63,284
Total debt 70,481 69,889 67,144 71,079 70,634 74,001 59,385 60,746 61,015 62,093 63,271 69,606 72,932 73,474 76,684 80,721 82,138 85,530 86,056 87,059 87,432 67,046
 
Stockholders’ equity (deficit) (183) 1,420 3,325 6,032 6,778 8,007 10,360 12,094 12,866 13,274 17,254 15,994 14,653 16,283 15,408 13,550 12,569 13,710 13,076 15,270 14,708 (7,415)
Solvency Ratio
Debt to equity1 49.22 20.19 11.78 10.42 9.24 5.73 5.02 4.74 4.68 3.67 4.35 4.98 4.51 4.98 5.96 6.53 6.24 6.58 5.70 5.94
Benchmarks
Debt to Equity, Competitors2
Amgen Inc. 7.57 9.24 10.23 8.02 10.57 12.75 10.37 7.90 9.08 11.52 10.64 10.60 15.10 40.23 4.97 4.57 3.98 3.50 3.51 3.13 3.21 3.36
Bristol-Myers Squibb Co. 2.82 2.86 3.04 2.90 3.08 3.38 1.35 1.30 1.18 1.19 1.27 1.20 1.29 1.42 1.24 1.20 1.23 1.23 1.34 0.90 0.95 0.94
Danaher Corp. 0.33 0.32 0.32 0.34 0.34 0.34 0.34 0.42 0.38 0.39 0.39 0.41 0.43 0.47 0.49 0.54 0.48 0.50 0.53 0.57 0.62 0.84
Eli Lilly & Co. 2.18 2.44 2.37 2.19 2.13 2.05 2.34 1.80 1.70 1.69 1.52 1.58 1.97 1.77 1.88 2.20 2.56 2.35 2.94 3.51 3.99 5.60
Gilead Sciences Inc. 1.27 1.30 1.38 1.26 1.28 1.44 1.09 1.12 1.19 1.20 1.19 1.20 1.30 1.32 1.27 1.29 1.53 1.59 1.73 1.68 1.34 1.09
Johnson & Johnson 0.65 0.67 0.51 0.51 0.58 0.48 0.43 0.42 0.61 0.75 0.52 0.43 0.43 0.44 0.46 0.48 0.48 0.51 0.56 0.59 0.48 0.45
Merck & Co. Inc. 0.72 0.72 0.80 0.86 0.87 0.85 0.93 0.85 0.95 0.66 0.67 0.68 0.73 0.78 0.87 0.74 0.80 1.16 1.26 0.98 1.12 1.07
Pfizer Inc. 0.70 0.69 0.73 0.73 0.79 0.75 0.81 0.66 0.66 0.36 0.37 0.40 0.46 0.44 0.50 0.53 0.56 0.58 0.63 0.97 0.99 0.80
Regeneron Pharmaceuticals Inc. 0.09 0.09 0.09 0.09 0.10 0.10 0.10 0.11 0.11 0.11 0.12 0.13 0.13 0.14 0.14 0.16 0.18 0.23 0.24 0.27 0.24 0.06
Thermo Fisher Scientific Inc. 0.70 0.69 0.63 0.72 0.75 0.78 0.75 0.78 0.78 0.83 0.78 0.67 0.72 0.81 0.85 0.56 0.51 0.53 0.63 0.66 0.71 0.70
Vertex Pharmaceuticals Inc. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q2 2025 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity (deficit)
= 70,481 ÷ -183 =

2 Click competitor name to see calculations.


The analysis of the quarterly financial data reveals several key trends in the company's leverage and equity position over the observed period.

Total Debt
The total debt exhibits a fluctuating but generally declining trend from the first quarter of 2020 through the end of 2023, decreasing from approximately $67 billion to about $59 billion. However, starting in early 2024, there is a notable increase in total debt, reaching nearly $70 billion by mid-2025. This resurgence suggests renewed borrowing or financing activities in the most recent quarters.
Stockholders’ Equity (Deficit)
Stockholders’ equity shows a significant recovery starting with a negative balance in the first quarter of 2020, quickly turning positive by the second quarter of 2020 and remaining positive through the end of 2023. The equity peaked around the fourth quarter of 2022 at approximately $17 billion before displaying a persistent decline starting in 2023. By mid-2025, equity has declined substantially, even becoming slightly negative again, indicating deteriorating net asset value or increasing liabilities surpassing assets.
Debt to Equity Ratio
The debt to equity ratio follows the inverse pattern of equity, with extremely high ratios at the start of the period (above 5x), then improving (falling to around 3.67 in late 2022), reflecting a stronger equity base relative to debt. However, from 2023 onwards, the ratio climbs sharply, reaching an extremely high level above 49x by mid-2025, primarily driven by the decline in equity and increase in debt levels. Such a high leverage ratio suggests elevated financial risk and possible solvency concerns.

In summary, the company experienced a phase of improvement in financial stability and equity strength from mid-2020 through late 2022. However, starting in 2023, the trends reversed with shrinking equity and rising debt, pushing leverage ratios to very high levels by mid-2025. This pattern signals increased financial risk and potential challenges in capital structure management moving forward.


Debt to Capital

AbbVie Inc., debt to capital calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in millions)
Short-term borrowings 5,556 1,593 3 2 1 1 10 17 12 14 16 17 9 34 54 64 6
Current portion of long-term debt and finance lease obligations 1,966 3,769 6,804 12,570 12,586 10,193 7,191 5,113 5,203 2,800 4,135 9,197 11,913 9,940 12,481 6,656 7,884 11,338 8,468 4,723 5,307 3,756
Long-term debt and finance lease obligations, excluding current portion 62,959 64,527 60,340 58,509 58,048 63,805 52,194 55,631 55,812 59,292 59,135 60,399 61,002 63,522 64,189 74,049 74,237 74,183 77,554 82,282 82,061 63,284
Total debt 70,481 69,889 67,144 71,079 70,634 74,001 59,385 60,746 61,015 62,093 63,271 69,606 72,932 73,474 76,684 80,721 82,138 85,530 86,056 87,059 87,432 67,046
Stockholders’ equity (deficit) (183) 1,420 3,325 6,032 6,778 8,007 10,360 12,094 12,866 13,274 17,254 15,994 14,653 16,283 15,408 13,550 12,569 13,710 13,076 15,270 14,708 (7,415)
Total capital 70,298 71,309 70,469 77,111 77,412 82,008 69,745 72,840 73,881 75,367 80,525 85,600 87,585 89,757 92,092 94,271 94,707 99,240 99,132 102,329 102,140 59,631
Solvency Ratio
Debt to capital1 1.00 0.98 0.95 0.92 0.91 0.90 0.85 0.83 0.83 0.82 0.79 0.81 0.83 0.82 0.83 0.86 0.87 0.86 0.87 0.85 0.86 1.12
Benchmarks
Debt to Capital, Competitors2
Amgen Inc. 0.88 0.90 0.91 0.89 0.91 0.93 0.91 0.89 0.90 0.92 0.91 0.91 0.94 0.98 0.83 0.82 0.80 0.78 0.78 0.76 0.76 0.77
Bristol-Myers Squibb Co. 0.74 0.74 0.75 0.74 0.75 0.77 0.57 0.56 0.54 0.54 0.56 0.54 0.56 0.59 0.55 0.55 0.55 0.55 0.57 0.47 0.49 0.48
Danaher Corp. 0.25 0.24 0.24 0.25 0.25 0.25 0.26 0.30 0.28 0.28 0.28 0.29 0.30 0.32 0.33 0.35 0.32 0.33 0.35 0.37 0.38 0.46
Eli Lilly & Co. 0.69 0.71 0.70 0.69 0.68 0.67 0.70 0.64 0.63 0.63 0.60 0.61 0.66 0.64 0.65 0.69 0.72 0.70 0.75 0.78 0.80 0.85
Gilead Sciences Inc. 0.56 0.57 0.58 0.56 0.56 0.59 0.52 0.53 0.54 0.55 0.54 0.54 0.56 0.57 0.56 0.56 0.60 0.61 0.63 0.63 0.57 0.52
Johnson & Johnson 0.39 0.40 0.34 0.34 0.37 0.32 0.30 0.30 0.38 0.43 0.34 0.30 0.30 0.31 0.31 0.33 0.32 0.34 0.36 0.37 0.33 0.31
Merck & Co. Inc. 0.42 0.42 0.44 0.46 0.46 0.46 0.48 0.46 0.49 0.40 0.40 0.41 0.42 0.44 0.46 0.42 0.44 0.54 0.56 0.50 0.53 0.52
Pfizer Inc. 0.41 0.41 0.42 0.42 0.44 0.43 0.45 0.40 0.40 0.26 0.27 0.28 0.32 0.31 0.33 0.35 0.36 0.37 0.39 0.49 0.50 0.45
Regeneron Pharmaceuticals Inc. 0.08 0.08 0.08 0.08 0.09 0.09 0.09 0.10 0.10 0.10 0.11 0.11 0.12 0.12 0.13 0.14 0.15 0.18 0.20 0.21 0.20 0.06
Thermo Fisher Scientific Inc. 0.41 0.41 0.39 0.42 0.43 0.44 0.43 0.44 0.44 0.45 0.44 0.40 0.42 0.45 0.46 0.36 0.34 0.35 0.39 0.40 0.42 0.41
Vertex Pharmaceuticals Inc. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q2 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= 70,481 ÷ 70,298 = 1.00

2 Click competitor name to see calculations.


Total Debt
The total debt exhibited a fluctuating trend over the observed periods. Beginning at approximately 67,046 million US dollars in March 2020, it increased significantly by mid-2020, reaching a peak near 87,432 million US dollars in June 2020. Subsequently, total debt generally decreased through 2022 and 2023, declining to around 59,385 million US dollars by the end of 2023. However, from March 2024 onwards, debt levels rose once more, reaching about 70,481 million US dollars by June 2025.
Total Capital
Total capital followed a somewhat similar pattern but with less volatility. It started at approximately 59,631 million US dollars in March 2020 and rose sharply to around 102,140 million US dollars by June 2020. After this peak, total capital gradually declined across the subsequent years, falling to roughly 69,745 million US dollars by December 2023. In 2024 and early 2025, total capital showed a mild recovery, increasing to approximately 70,298 million US dollars by June 2025.
Debt to Capital Ratio
The debt to capital ratio revealed notable variability correlating with the movements in debt and total capital. Initially, in March 2020, the ratio was elevated at 1.12, indicative of debt exceeding capital at that time. It then sharply decreased to approximately 0.85 by mid-2020 and remained relatively stable between 0.79 and 0.87 through 2021 to 2023, suggesting a more balanced capital structure during this period. From 2024 onwards, the ratio increased steadily, moving from 0.90 in early 2024 to a level of 1.00 by mid-2025, indicating a shift towards higher leverage, with debt equaling total capital.
Summary Insights
Overall, the financial data reveals an initial surge and subsequent decline in both total debt and total capital from 2020 through 2023, followed by a period of increased leverage starting in 2024. The debt to capital ratio's rise to 1.00 by mid-2025 suggests the company assumed a more leveraged position relative to its capital base during the later periods. The interplay of these metrics indicates dynamic capital management, with periods of deleveraging and increasing leverage reflecting responses to evolving financial conditions or strategic decisions.

Debt to Assets

AbbVie Inc., debt to assets calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in millions)
Short-term borrowings 5,556 1,593 3 2 1 1 10 17 12 14 16 17 9 34 54 64 6
Current portion of long-term debt and finance lease obligations 1,966 3,769 6,804 12,570 12,586 10,193 7,191 5,113 5,203 2,800 4,135 9,197 11,913 9,940 12,481 6,656 7,884 11,338 8,468 4,723 5,307 3,756
Long-term debt and finance lease obligations, excluding current portion 62,959 64,527 60,340 58,509 58,048 63,805 52,194 55,631 55,812 59,292 59,135 60,399 61,002 63,522 64,189 74,049 74,237 74,183 77,554 82,282 82,061 63,284
Total debt 70,481 69,889 67,144 71,079 70,634 74,001 59,385 60,746 61,015 62,093 63,271 69,606 72,932 73,474 76,684 80,721 82,138 85,530 86,056 87,059 87,432 67,046
 
Total assets 137,182 136,165 135,161 143,422 141,937 148,874 134,711 136,221 135,367 134,544 138,805 141,325 143,186 143,211 146,529 148,858 147,972 150,501 150,565 149,621 149,530 91,199
Solvency Ratio
Debt to assets1 0.51 0.51 0.50 0.50 0.50 0.50 0.44 0.45 0.45 0.46 0.46 0.49 0.51 0.51 0.52 0.54 0.56 0.57 0.57 0.58 0.58 0.74
Benchmarks
Debt to Assets, Competitors2
Amgen Inc. 0.64 0.64 0.65 0.66 0.69 0.69 0.67 0.67 0.68 0.69 0.60 0.61 0.62 0.62 0.54 0.58 0.55 0.52 0.52 0.53 0.53 0.52
Bristol-Myers Squibb Co. 0.52 0.54 0.54 0.53 0.55 0.56 0.42 0.41 0.40 0.40 0.41 0.40 0.42 0.44 0.41 0.40 0.41 0.41 0.43 0.36 0.36 0.36
Danaher Corp. 0.21 0.21 0.21 0.22 0.22 0.22 0.22 0.25 0.23 0.23 0.23 0.24 0.25 0.26 0.27 0.29 0.26 0.27 0.28 0.30 0.31 0.38
Eli Lilly & Co. 0.40 0.43 0.43 0.41 0.40 0.41 0.39 0.35 0.34 0.36 0.33 0.33 0.36 0.35 0.35 0.35 0.35 0.35 0.36 0.39 0.39 0.42
Gilead Sciences Inc. 0.45 0.44 0.45 0.43 0.44 0.45 0.40 0.40 0.40 0.41 0.40 0.40 0.42 0.42 0.39 0.41 0.44 0.45 0.46 0.48 0.43 0.40
Johnson & Johnson 0.26 0.27 0.20 0.20 0.23 0.20 0.18 0.18 0.24 0.27 0.21 0.18 0.18 0.19 0.19 0.19 0.19 0.19 0.20 0.22 0.19 0.18
Merck & Co. Inc. 0.30 0.30 0.32 0.32 0.34 0.32 0.33 0.33 0.35 0.29 0.28 0.28 0.30 0.30 0.31 0.28 0.29 0.34 0.35 0.32 0.34 0.33
Pfizer Inc. 0.30 0.30 0.30 0.31 0.32 0.31 0.32 0.30 0.30 0.18 0.18 0.19 0.21 0.20 0.21 0.22 0.23 0.25 0.26 0.35 0.36 0.31
Regeneron Pharmaceuticals Inc. 0.07 0.07 0.07 0.07 0.07 0.08 0.08 0.08 0.09 0.09 0.09 0.10 0.10 0.10 0.11 0.11 0.13 0.15 0.16 0.17 0.15 0.05
Thermo Fisher Scientific Inc. 0.35 0.35 0.32 0.35 0.36 0.37 0.35 0.36 0.36 0.37 0.35 0.32 0.33 0.36 0.37 0.29 0.28 0.28 0.31 0.33 0.35 0.34
Vertex Pharmaceuticals Inc. 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q2 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= 70,481 ÷ 137,182 = 0.51

2 Click competitor name to see calculations.


The financial data reveals several notable trends regarding debt levels, assets, and the debt-to-assets ratio over the examined quarterly periods.

Total Debt
Total debt started at a level of approximately 67 billion US dollars in the first quarter of 2020 and experienced a significant increase reaching a peak near 87 billion in mid-2020. Subsequently, there was a gradual reduction in debt levels throughout 2021 and into 2022, with total debt decreasing steadily from around 85 billion to approximately 63 billion by the end of 2022. In 2023, the debt level stabilized near 61 billion and remained relatively flat until the end of the year. However, starting in early 2024, total debt reversed this downward trend, increasing again to around 70 billion by mid-2025. The recent rise in debt suggests a shift in the company's financing or investment strategy during this period.
Total Assets
Total assets showed notable fluctuations over the period. Initially, assets increased sharply from about 91 billion in early 2020 to near 150 billion by the middle of 2020. Subsequently, there was a mild decline in total assets, fluctuating around the 140-150 billion range until the end of 2021. From 2022 onward, total assets experienced a gradual decrease reaching a low near 134 billion in early 2023. However, asset levels stabilized and showed some moderate growth in late 2023 and early 2024, peaking again around 148 billion mid-2024, before experiencing a mild decline towards mid-2025 to roughly 137 billion. This pattern reflects some volatility but overall indicates the company's asset base remained broadly stable after peaking in 2020.
Debt to Assets Ratio
The debt to assets ratio declined consistently from 0.74 in early 2020 to around 0.44 by late 2023, indicating an improvement in the capital structure with lower leverage over time. The reduction is primarily driven by declining debt levels alongside relatively stable asset values. Nonetheless, starting in 2024, the ratio reversed its downward trend, gradually rising back toward 0.51 by mid-2025. This increase correlates with the uptick in debt levels while assets experienced only a modest change, reflecting a renewed increase in leverage.

In summary, the company reduced its leverage substantially between 2020 and 2023 through a combination of decreasing debt and maintaining asset levels. However, beginning in 2024, the financial structure shifted as debt increased, leading to higher leverage ratios. The asset base experienced growth and decline cycles but remained within a relatively narrow band after the 2020 peak. These trends suggest carefully managed deleveraging in the first phase, followed by a strategic rebound in debt exposure in the most recent periods.


Financial Leverage

AbbVie Inc., financial leverage calculation (quarterly data)

Microsoft Excel
Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in millions)
Total assets 137,182 136,165 135,161 143,422 141,937 148,874 134,711 136,221 135,367 134,544 138,805 141,325 143,186 143,211 146,529 148,858 147,972 150,501 150,565 149,621 149,530 91,199
Stockholders’ equity (deficit) (183) 1,420 3,325 6,032 6,778 8,007 10,360 12,094 12,866 13,274 17,254 15,994 14,653 16,283 15,408 13,550 12,569 13,710 13,076 15,270 14,708 (7,415)
Solvency Ratio
Financial leverage1 95.89 40.65 23.78 20.94 18.59 13.00 11.26 10.52 10.14 8.04 8.84 9.77 8.80 9.51 10.99 11.77 10.98 11.51 9.80 10.17
Benchmarks
Financial Leverage, Competitors2
Amgen Inc. 11.83 14.40 15.63 12.07 15.34 18.51 15.59 11.83 13.31 16.59 17.79 17.44 24.51 64.62 9.13 7.91 7.25 6.70 6.69 5.90 6.10 6.50
Bristol-Myers Squibb Co. 5.43 5.32 5.67 5.46 5.56 6.01 3.23 3.15 2.92 2.96 3.12 3.01 3.08 3.26 3.04 2.98 3.01 2.99 3.13 2.50 2.61 2.59
Danaher Corp. 1.56 1.56 1.57 1.57 1.57 1.56 1.58 1.67 1.64 1.65 1.68 1.72 1.76 1.80 1.84 1.90 1.82 1.87 1.92 1.92 1.97 2.22
Eli Lilly & Co. 5.52 5.67 5.55 5.31 5.30 4.99 5.94 5.16 4.95 4.75 4.65 4.71 5.51 5.03 5.44 6.21 7.42 6.79 8.27 9.10 10.25 13.35
Gilead Sciences Inc. 2.83 2.95 3.05 2.95 2.93 3.21 2.72 2.80 2.95 2.95 2.97 2.97 3.11 3.17 3.23 3.13 3.45 3.56 3.76 3.49 3.10 2.71
Johnson & Johnson 2.46 2.48 2.52 2.54 2.53 2.46 2.44 2.33 2.55 2.77 2.44 2.35 2.33 2.39 2.46 2.55 2.54 2.62 2.76 2.65 2.51 2.53
Merck & Co. Inc. 2.40 2.38 2.53 2.64 2.58 2.62 2.84 2.59 2.70 2.30 2.37 2.41 2.48 2.61 2.77 2.61 2.72 3.37 3.62 3.08 3.28 3.24
Pfizer Inc. 2.32 2.30 2.42 2.38 2.47 2.40 2.54 2.22 2.22 1.94 2.06 2.10 2.24 2.23 2.35 2.37 2.43 2.31 2.44 2.74 2.77 2.56
Regeneron Pharmaceuticals Inc. 1.28 1.28 1.29 1.28 1.28 1.27 1.27 1.29 1.28 1.28 1.29 1.29 1.32 1.32 1.36 1.37 1.42 1.48 1.56 1.59 1.59 1.30
Thermo Fisher Scientific Inc. 2.00 2.01 1.96 2.05 2.08 2.13 2.11 2.14 2.15 2.24 2.21 2.08 2.14 2.26 2.33 1.90 1.84 1.88 2.00 2.01 2.06 2.05
Vertex Pharmaceuticals Inc. 1.40 1.39 1.37 1.42 1.36 1.29 1.29 1.32 1.32 1.31 1.30 1.28 1.31 1.31 1.33 1.32 1.33 1.35 1.35 1.39 1.36 1.38

Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q2 2025 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity (deficit)
= 137,182 ÷ -183 =

2 Click competitor name to see calculations.


The analysis of the quarterly financial data reveals several key trends over the observed periods. The total assets demonstrate a fluctuating but generally declining pattern from the high point recorded around mid-2020 through to the later dates in 2025. After reaching approximately US$150.5 billion in early 2020, the total assets decreased steadily to around US$134.5 billion at the end of 2023. Subsequently, some recovery is noted, with values rising again to approximately US$148.9 billion in early 2024 before declining once more toward US$137.2 billion by mid-2025.

Stockholders’ equity shows notable volatility throughout the periods. Initially negative in early 2020, stockholders’ equity sharply improves by mid-2020, becoming positive and increasing to a level of around US$15 billion before displaying a fluctuating yet generally downward trend post-2021. From a peak near US$17.2 billion at the end of 2022, equity diminishes noticeably to negative territory by mid-2025, indicating potential financial stress or increased liability levels relative to assets.

The financial leverage ratio, which reflects the proportion of total assets to equity, undergoes significant changes that align with the equity movement. It begins at a relatively high level around 10, increases steadily through 2021 and 2022, fluctuating between 8 and 13, before surging sharply from early 2024 onward. The ratio escalates dramatically to levels above 40 by the end of 2024 and an extreme 95.89 in mid-2025. This sharp increase in leverage suggests a substantial rise in debt or liabilities, possibly linked with the decreasing equity base, which could imply elevated financial risk in the most recent periods.

Total Assets
Show a declining trend from mid-2020 high to late 2023, with intermittent recovery in 2024 before further decline into 2025.
Stockholders’ Equity
Shifted from negative to positive early on, peaked around end of 2022, followed by a consistent decrease leading to negative territory in mid-2025.
Financial Leverage
Remains stable initially, then rises modestly through 2021 and 2022, before sharply increasing after 2023, indicating increased financial risk due to higher debt levels against a shrinking equity base.